Navigation Links
Genomic profiling of lung tumors helps doctors choose most effective treatment
Date:9/28/2007

DURHAM, N.C. -- Determining the genetic profile of a particular lung tumor can help clinicians make the crucial decision about which chemotherapy treatment to try first.

A new study led by researchers from the Duke University Comprehensive Cancer Center and the Duke Institute for Genome Sciences & Policy (IGSP) found distinct differences in the susceptibility different tumors have to widely used chemotherapy drugs.

We were able to predict which tumors would be most likely to respond to standard first-line therapy and which would respond better to what has traditionally been a second-line therapy, based on gene expression profiling, said David Hsu, M.D., Ph.D. an oncologist at Duke and lead author on the publication. This represents a big step in the move toward individualized medicine. This could also make a huge difference in the treatment of patients with late-stage lung cancer, as most of these patients gain the most benefit from their initial treatment strategy.

The researchers published their findings in the October 1, 2007 issue of the Journal of Clinical Oncology. The study was funded by the Jimmy V Foundation and the National Cancer Institute.

Researchers looked at the sensitivity of multiple cancerous cell lines to cisplatin, the most commonly used agent in the treatment of lung cancer. After determining which cell lines were responsive to cisplatin they looked at the RNA of these tumors and generated a genomic signature -- a pattern of gene expression particular to each individual sample. They were able to draw conclusions about which genes were turned on and which were turned off in these samples, and subsequently created a genomic map for cisplatin sensitivity. The genomic map was then applied to 91 non-small cell lung cancer (NSCLC) tumor samples to determine which tumors were most likely to be responsive to cisplatin, Hsu said.

We found that tumors known to be sensitive to cisplatin expressed certain
'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Upcoming Hemogenomics Centre in Bangalore
2. Evoprinter, a multigenomic comparative tool for rapid identification of functionally important DNA
3. International Conference On Malaria - Laveran To Genomics
4. LINK Applied Genomics Programme Promises To Revolutionize Healthcare Systems
5. Nutrigenomics here comes a team to better your future!
6. Genomic tests for better cancer treatment
7. Web-Based Genomics Tool Designed to Help Predict Disease Susceptibility
8. AutoGenomics Addresses TB Crisis With a Genetic Drug Resistance Test
9. Pharmacogenomic Market Gaining Greater Acceptance Across Europe
10. Nutrient Profiling System Launched By Food Officials in UK
11. Proteomic Profiling Can Detect Preterm Birth Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Wa (PRWEB) July 14, 2014 Dry eyes, ... of aging anymore. As recent research have pointed out, today’s ... from dry eyes as a result of using laptops ... or daily lives. , Because of this phenomenon, it has ... that will not just cure them from having dry eyes, ...
(Date:7/14/2014)... Cabin Chiang Mai, Asia’s leading inpatient addiction treatment centre, ... – a free comprehensive aftercare service for clients who ... they live in the world. , The Cabin firmly ... maintain their recovery after successfully completing primary treatment should ... As a chronic disease, addicts in recovery are always ...
(Date:7/14/2014)... 14, 2014 EurekaMag.com has newly published ... is a contagious liver disease that ranges in ... to a serious, lifelong illness that attacks the liver. ... have chronic Hepatitis C virus infection of which approximately ... research category covers all studies on Hepatitis C ...
(Date:7/14/2014)... According to the Boost Your Bust book review recently ... want to learn how to increase the size of their breasts ... chapters including:, , Chapter 1 – What Are ... 2 – How Natural Breast Enlargement Works , Chapter ... Chapter 4 – The Groundwork , Chapter ...
(Date:7/14/2014)... Vaginal Mesh lawsuit claims continue to ... mesh manufacturers in the U.S. District Court, Southern District ... federal complaints are pending against pelvic mesh manufacturers that ... (MDL No. 2325), and C.R. Bard, Inc., (MDL No. ... Mesh lawsuit claims pending, according to statistics from the ...
Breaking Medicine News(10 mins):Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 2Health News:Dry Eye Handbook Review | Taking Care of One’s Vision by Using Natural Methods – Vinamy.com 3Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 2Health News:Boost Your Bust Book Review Exposes Jenny Bolton's Breast Enhancement Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5
... Lube Leader Reaches Halfway Point in Campaign to Support American ... Heart Association,s Go Red For Women(TM) Movement, HOUSTON, Feb. ... to its goal of raising $1 million for the,American Heart ... Heart Month are almost in the rear-view mirror, Jiffy,Lube wants ...
... according to a study of more than 77,000 vitamin ... risk of developing it. , Our study of supplemental ... show any evidence for a decreased risk of lung ... of the University of Washington, in Seattle. Indeed, increasing ...
... and a decision algorithm, rather than standard hospital protocols, ... patients with severe sepsis or septic shock can reduce ... costs all without adverse effects on patients, according to ... possible to customize antibiotic treatment duration in patients with ...
... UT Southwestern Medical Center have determined that the level, or ... children with sickle cell anemia who are at an increased ... have also found that a published method used to predict ... , Stroke is a serious but increasingly preventable complication of ...
... affected by ... rare diseases, NEW YORK, Feb. ... Day will be launched on Friday 29,February...because it,s a rare day that ... Shire plc at:, http://media.medialink.com/WebNR.aspx?story=34701 ), Collectively, rare diseases aren,t ...
... to Reliance on Spill-Proof,Cups, GLENDALE, Calif., Feb. 28 ... Dental Hygienists, Association,(CDHA) today urged parents and caregivers to ... "We all know that sippy cups are a godsend ... "But they need to be used wisely and,properly in ...
Cached Medicine News:Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 2Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 3Health News:Jiffy Lube(R) Continues Drive Against Heart Disease with Maintenance Partners for Life Campaign 4Health News:Certain vitamin supplements may increase lung cancer risk, especially in smokers 2Health News:Customized treatments for sepsis lower treatment time and reduce length of ICU stays 2Health News:UT Southwestern researchers investigate predictors for sickle-cell-anemia complications 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 2Health News:VIDEO from Medialink and Shire plc: Rare Diseases Must Be Top of the Health Agenda 3Health News:California Dental Hygienists Offer Tips for Safe Sippy Cup Use 2
(Date:7/14/2014)... , July 14, 2014 ... a technology partnership with global bioengineering leader ... technology for quick-to-market products. The ... DNA2.0,s machine learning optimization technologies, such as ... the process of engineering proteins in the ...
(Date:7/14/2014)... , July 14, 2014 Sinovac Biotech Ltd. (NASDAQ: ... , announced today that it will hold its 2014 Annual Meeting ... The meeting will be held at No. 39 Shangdi Xi Road, Haidian ... of July 9, 2014 will be eligible to vote and are invited ... approve the re-election of Weidong Yin , Yuk Lam Lo ...
(Date:7/14/2014)... 14, 2014  Mylan Inc. (NASDAQ: MYL ) ... with Abbott (NYSE: ABT ... non-U.S. developed markets specialty and branded generics business ("the Assets") ... will receive 105 million shares of the combined company ... $50.20 on Friday, July 11, 2014, representing an approximately 21% ...
Breaking Medicine Technology:Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3Sinovac Schedules 2014 Annual Meeting of Shareholders 2Sinovac Schedules 2014 Annual Meeting of Shareholders 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 2Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 3Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 4Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 5Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 6Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 7Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 8Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 9Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 10Mylan To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction 11
... Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) management ... Tuesday, October 25th at 11:30 a.m. Pacific/ 2:30 p.m. Eastern/ ... the Palace Hotel in San Francisco. The ... for replay after the presentation. The webcast can be accessed ...
... Colo., Oct. 18, 2011 SomaLogic, Inc., announced today ... with Novartis to use its unique proprietary proteomics technology ... "We are excited by this opportunity to ... robust biomarkers, validate novel drug targets, and even develop ...
Cached Medicine Technology:SomaLogic Announces Research Agreement with Leading Global Pharmaceutical Company to Accelerate Pharmaceutical Discovery and Development 2
The ENDO MINI-RETRACT™ 5 mm instrument has application in a variety of gynecologic, abdominal, urologic, thoracic and endoscopic procedures for temporary retraction of tissue and small tubular ...
The ENDO PEANUT™ instrument has indications in endoscopic surgery for swabbing small amounts of ?uid or for blunt dissection of soft tissue(s) and structures, or as an aid in controlling minor ...
... Introducing the widest offering of single-use instruments on ... long 43cm lengths for Bariatric Surgery. , ... Extended insulation covers the pivot points to reduce ... A 4mm universal cord, which eliminates gapping at ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: